Halozyme Therapeutics total liabilities and share holders equity for the quarter ending December 31, 2024 was $2.063B, a 19.05% increase year-over-year.
Halozyme Therapeutics total liabilities and share holders equity for 2024 was $2.063B, a 19.05% increase from 2023.
Halozyme Therapeutics total liabilities and share holders equity for 2023 was $1.733B, a 5.88% decline from 2022.
Halozyme Therapeutics total liabilities and share holders equity for 2022 was $1.842B, a 66.74% increase from 2021.
Halozyme Therapeutics Total Liabilities and Share Holders Equity 2010-2024 | HALO